Updated Jul 16, 2026
Valamehr Bahram has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $75K.

Bahram Valamehr is the President and CEO of Fate Therapeutics Inc, a clinical-stage biopharmaceutical company focused on developing programmed cellular immunotherapies for cancer and autoimmune disorders. He has been involved in the company's strategic direction and operational management.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-21 | FATE | FATE THERAPEUTICS INC | S — Open-market sale | 28.9K | $1.88 | $54K |
| 2026-01-16 | FATE | FATE THERAPEUTICS INC | A — Grant or award | 335.0K | $0.00 | |
| 2026-01-12 | FATE | FATE THERAPEUTICS INC | S — Open-market sale | 5.2K | $1.07 | $6K |
| 2025-08-04 | FATE | FATE THERAPEUTICS INC | S — Open-market sale | 14.5K | $1.06 | $15K |
Bahram Valamehr is the President and CEO of Fate Therapeutics Inc, a clinical-stage biopharmaceutical company focused on developing programmed cellular immunotherapies for cancer and autoimmune disorders. He has been involved in the company's strategic direction and operational management.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 3 open-market sales ($75K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Valamehr Bahram profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.